This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous murepavadin given with ertapenem versus an anti-pseudomonal β-lactam based antibiotic in the treatment of nosocomial pneumonia in adult subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
2
Murepavadin + ertapenem
Either meropenem or piperacillin-tazobactam
Research site
Iowa City, Iowa, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research site
Břeclav, Czechia
Research site
Kolín, Czechia
All cause mortality rates
Time frame: 28 days after start of study treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research site
Argenteuil, France
Research site
Hadera, Israel
Research site
Tel Aviv, Israel